ExpreS2ion announces poster presentation on ES2B-C001 at the AACR Annual Meeting 2023

Hørsholm, Denmark, 18 April 2023 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") today announces that the company through its research collaboration partners at University of Bologna presented a poster on ES2B-C001, our unique HER2-VLP breast cancer vaccine candidate, at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 14-19, 2023, in Orlando, Florida.

The presentation poster titled “Preclinical activity of ES2B-C001, a human candidate HER-2 virus-like particle (VLP) vaccine, against mammary carcinoma onset and metastasis” concludes, that:

• ES2B-C001 vaccination inhibited the onset, growth, and metastatic spread of HER-2 positive mammary carcinomas in mice.

• The vaccine induced strong and persistent antibody responses that inhibited human HER-2+ breast and gastric cancer cells in vitro.

• ES2B-C001 is a promising candidate vaccine for the therapy of human tumours expressing HER-2. Preclinical results warrant further development towards human clinical studies.

A copy of the poster can be found at the company webpage at https://expres2ionbio.com/meet-us/

Certified Adviser

Svensk Kapitalmarknadsgranskning AB

For further information about ExpreS²ion Biotech Holding AB, please contact:

Bent U. Frandsen, CEO
Telephone: +45 4256 6869
E-mail: buf@expres2ionbio.com

Keith Alexander, CFO

Telephone: +45 5131 8147

E-mail: ka@expres2ionbio.com 

About ExpreS²ion

ExpreS²ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS²ion Biotech Holding AB with company register number 559033-3729. ExpreS²ion has developed a unique technology platform, ExpreS², for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS² is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS²ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS²ion owns 34%. For additional information, please visit www.expres2ionbio.com.